Saturday 17 October 2026
Export LGND’s income statement to Excel — free account
Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.
295.54
2.96
−0.99%
Follow LGND
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 144.13 | 12.54 | 2.13 | 0.00 | 27.85 | 0.00 | 23.79 | 0.00 | 30.01 |
Piotroski F-Score |
5 | 8 | 7 | 5 | 5 | 7 | 4 | 6 | 5 | 6 |
P/S ratio |
12.22 | 12.89 | 7.12 | 10.27 | 6.14 | 6.63 | 5.68 | 9.53 | 11.73 | 13.64 |
Altman Z-Score |
2.33 | 3.68 | 2.66 | 4.14 | 1.89 | 3.34 | 5.45 | 10.04 | 11.78 | 5.45 |
P/FCF ratio |
32.34 | 19.20 | 9.42 | 0.00 | 20.56 | 23.24 | 9.96 | 0.00 | 21.84 | 60.02 |
Altman Z″-Score (non-manufacturers) |
(1.17) | 0.26 | 5.22 | 10.46 | 4.19 | 5.61 | 7.17 | 12.55 | 11.45 | 6.75 |
Beneish M-Score |
(1.78) | (2.41) | (2.08) | (0.57) | (1.56) | (1.79) | (3.98) | (1.93) | (3.22) | (4.02) |
P/Operating CF |
71.13 | 58.09 | 54.99 | (168.39) | 1,869.86 | 57.97 | 20.83 | 155.09 | 68.83 | 79.63 |
P/B ratio |
3.90 | 4.55 | 3.19 | 1.61 | 1.42 | 1.95 | 1.86 | 1.78 | 2.36 | 3.59 |
Price to Tangible BV |
34.54 | 27.68 | 8.03 | 2.80 | 0.00 | 4.88 | 8.00 | 4.20 | 4.27 | 5.30 |
EV/Sales |
13.15 | 13.19 | 6.58 | 6.70 | 6.38 | 6.56 | 5.04 | 8.86 | 10.63 | 12.77 |
EV/EBITDA |
21.57 | 20.37 | 7.62 | 0.93 | 11.59 | 9.23 | 17.87 | 24.55 | 150.69 | 48.15 |
EV/Operating CF |
23.60 | 21.01 | 8.52 | (27.47) | 19.11 | 20.10 | 7.17 | 23.46 | 18.30 | 69.35 |
EV/FCF |
34.80 | 19.64 | 8.70 | (22.97) | 21.36 | 22.98 | 8.84 | (301.84) | 19.80 | 56.19 |
Quick Ratio |
0.69 | 0.95 | 10.09 | 65.38 | 4.70 | 10.39 | 2.50 | 12.49 | 8.32 | 21.83 |
Current Ratio |
0.72 | 0.99 | 10.58 | 66.09 | 5.00 | 11.15 | 2.67 | 14.15 | 8.93 | 22.23 |
Net Debt/EBITDA |
1.53 | 0.46 | (0.63) | (0.49) | 0.43 | (0.11) | (2.26) | (3.59) | (22.58) | (4.36) |
Debt/Assets |
40.31% | 36.27% | 50.47% | 42.81% | 33.05% | 24.79% | 11.37% | 0.00% | 0.00% | 28.59% |
Debt/Equity |
0.71 | 0.61 | 1.13 | 0.83 | 0.63 | 0.39 | 0.15 | 0.00 | 0.00 | 0.44 |
Asset Turnover |
0.20 | 0.22 | 0.26 | 0.09 | 0.11 | 0.18 | 0.19 | 0.17 | 0.19 | 0.21 |
Operating CF/Net income |
(37.12) | 7.05 | 1.35 | (0.05) | (18.29) | 1.38 | (4.13) | 0.95 | (24.07) | 0.40 |
Capex/Depreciation |
(0.87) | 0.21 | (0.20) | (0.04) | (0.06) | (0.12) | (0.34) | (1.51) | (0.35) | (0.03) |
Interest Coverage |
3.42 | 5.06 | 3.39 | 22.58 | 1.37 | 5.29 | 1.69 | 18.20 | (7.44) | 8.70 |
| (0.57%) | 3.39% | 29.84% | 94.76% | (0.40%) | 7.47% | (4.70%) | 8.03% | (0.53%) | 13.47% | |
| (0.30%) | 1.97% | 14.84% | 45.67% | (0.21%) | 4.30% | (3.24%) | 6.73% | (0.47%) | 9.95% | |
ROIC |
6.20% | 9.64% | 24.17% | 149.54% | 3.13% | 8.10% | 0.40% | 1.41% | (2.50%) | 3.62% |
Return on Tangible Assets |
2.63% | 530.91% | 18.06% | 56.50% | (0.72%) | 13.10% | (18.82%) | 22.08% | (1.30%) | 15.66% |
Average Days of Receivables |
49.24 | 66.21 | 81.28 | 126.69 | 131.81 | 138.49 | 65.17 | 109.27 | 92.70 | 83.12 |
Research and Development Expense of Revenue |
19.47% | 19.06% | 11.08% | 46.48% | 24.76% | 13.29% | 18.39% | 18.69% | 12.82% | 30.28% |
Selling, General and Administrative Expense of Revenue |
25.38% | 20.31% | 15.01% | 34.82% | 36.69% | 19.37% | 35.70% | 40.20% | 47.06% | 34.48% |
Intangible Assets out of Total Assets |
0.50 | 0.50 | 0.27 | 0.22 | 0.58 | 0.38 | 0.60 | 0.51 | 0.39 | 0.21 |
Share Based Compensation of Revenue |
17.34% | 17.66% | 8.29% | 20.38% | 18.79% | 16.06% | 30.72% | 19.60% | 24.58% | 17.48% |
Graham Net Nets |
(0.07) | (0.02) | 0.10 | 0.32 | (0.15) | (0.01) | 0.09 | 0.12 | 0.11 | 0.08 |
Graham Number |
0.00 | 16.02 | 63.45 | 166.79 | 0.00 | 62.00 | 0.00 | 52.64 | 0.00 | 86.35 |
Earnings Yield |
(0.09%) | 0.69% | 7.97% | 47.05% | (0.23%) | 3.59% | (3.00%) | 4.20% | (0.05%) | 3.33% |
Free Cash Flow Yield |
3.09% | 5.21% | 10.61% | (2.84%) | 4.86% | 4.30% | 10.04% | (0.31%) | 4.58% | 1.67% |
Revenue per Share |
5.23 | 6.71 | 11.88 | 6.33 | 10.11 | 14.52 | 11.63 | 7.59 | 9.14 | 13.86 |
Operating CF per Share |
2.92 | 4.21 | 9.17 | (1.54) | 3.37 | 4.74 | 8.17 | 2.87 | 5.31 | 2.55 |
Capex per Share |
(0.94) | 0.23 | (0.51) | (0.13) | (0.19) | (0.50) | (1.06) | (3.09) | (0.67) | (0.05) |
Free Cash Flow per Share |
1.98 | 4.44 | 8.66 | (1.68) | 3.18 | 4.24 | 7.12 | (0.22) | 4.64 | 2.50 |
Cash per Share |
6.77 | 9.59 | 36.57 | 56.32 | 25.41 | 20.51 | 12.56 | 9.85 | 14.55 | 39.11 |
Shareholders Equity per Share |
16.38 | 19.01 | 26.51 | 40.39 | 43.84 | 49.38 | 35.42 | 40.52 | 45.40 | 52.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.38 | 19.01 | 26.51 | 40.39 | 43.84 | 49.38 | 35.42 | 40.52 | 45.40 | 52.60 |
Free Cash Flow |
41.19 | 93.47 | 183.17 | (31.89) | 51.49 | 70.53 | 120.02 | (3.85) | 84.84 | 48.31 |
Working Capital |
(64.08) | (1.85) | 788.29 | 1,106.64 | 400.45 | 423.09 | 164.79 | 220.65 | 294.45 | 794.82 |
Capital Expenditures |
(19.54) | 4.90 | (10.89) | (2.55) | (3.10) | (8.27) | (17.83) | (53.43) | (12.21) | (1.05) |
Net Current Asset Value |
(97.24) | (34.21) | 170.65 | 395.96 | (152.20) | (11.68) | 98.42 | 151.13 | 220.22 | 288.85 |
EV/EBIT |
32.66 | 27.33 | 10.10 | 1.00 | 27.82 | 15.25 | 325.52 | 97.41 | 0.00 | 83.48 |
Capex to Sales |
0.18 | (0.03) | 0.04 | 0.02 | 0.02 | 0.03 | 0.09 | 0.41 | 0.07 | 0.00 |
Price to Operating Income |
30.35 | 26.72 | 10.94 | 1.53 | 26.78 | 15.43 | 366.74 | 104.74 | 0.00 | 89.17 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
12.40 | 5.52 | 9.91 | 8.83 | 3.64 | 5.14 | 4.19 | 2.27 | 2.27 | 0.00 |
Cash ROIC |
5.68% | 11.06% | 9.29% | (1.29%) | 3.28% | 4.75% | 13.39% | (0.44%) | 7.74% | 2.18% |
Accounts Receivable Turnover |
10.44 | 7.00 | 6.16 | 2.46 | 3.24 | 3.21 | 3.10 | 3.53 | 4.09 | 5.18 |
Accounts Payable Turnover |
1.63 | 2.15 | 1.97 | 3.44 | 9.81 | 10.20 | 7.71 | 2.72 | 2.89 | 3.44 |
Inventory Turnover |
3.13 | 1.70 | 1.10 | 1.57 | 1.80 | 2.31 | 2.60 | 0.56 | 0.58 | 1.25 |
Average Days of Payables |
179.13 | 153.66 | 240.93 | 77.84 | 45.40 | 49.33 | 36.67 | 84.27 | 172.48 | 81.23 |
Days of Inventory on Hand |
125.99 | 297.46 | 410.33 | 234.69 | 317.82 | 160.42 | 91.85 | 832.26 | 465.20 | 228.95 |
Average Receivables |
10.44 | 20.15 | 40.79 | 48.87 | 50.41 | 75.36 | 63.34 | 37.18 | 40.88 | 51.75 |
Average Payables |
3.41 | 2.50 | 3.22 | 3.30 | 3.10 | 6.09 | 6.86 | 3.87 | 3.83 | 4.24 |
Average Inventory |
1.78 | 3.15 | 5.75 | 7.21 | 16.89 | 26.91 | 20.31 | 18.63 | 19.04 | 11.62 |
Average Assets |
552.32 | 636.30 | 965.91 | 1,377.86 | 1,428.60 | 1,329.94 | 1,030.13 | 774.94 | 864.50 | 1,251.21 |
Average Common Equity |
289.29 | 370.54 | 480.35 | 664.07 | 738.38 | 765.34 | 709.32 | 649.20 | 765.68 | 923.83 |
Columns are period end dates